Case Type: Mergers & Acquisitions

Carisma Therapeutics Inc. (NASDAQ: CARM) related to its to OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company.

Verve Therapeutics, Inc. (NASDAQ: VERV) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones.

CureVac N.V. (NASDAQ: CVAC) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.

Cantaloupe, Inc. (NASDAQ: CTLP) related to its sale to 365 Retail Markets, LLC for $11.20 per share in cash.

BGSF, Inc.’s (NYSE: BGSF) related to the sale of its Professional Division to INSPYR Solutions for $99 million.

M2i Global, Inc. (OTCQB: MTWO) related to its merger with Volato Group, Inc. Upon completion of the proposed merger, M2i will own approximately 90% of the combined company.

Elevation Oncology, Inc. (NASDAQ: ELEV) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% … Read more

Crown Electrokinetics Corp. (OTCMKTS: CRKN) related to its sale to Crown EK Acquisition LLC for $3.15 per share.

Blueprint Medicines Corporation (NASDAQ: BPMC) related to it sale to Sanofi. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR … Read more

Atai Life Sciences N.V. (NASDAQ: ATAI) related to the acquisition of Beckley Psytech Limited.